Key multiple sclerosis companies such as Mapi Pharma, Novartis, Immunic, Biocad ... and risks in the multiple sclerosis clinical trial landscape. Multiple Sclerosis Overview Multiple sclerosis is a ...

Ames Gross of Pacific Bridge Medical provides an overview ... In 2012, Watson Pharmaceuticals inherited a Malaysian facility after it acquired Ascent Pharmahealth. Novartis – which currently ...

Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will ...

The Nasal Drug Delivery Technology Market is driven by the rising demand for non-invasive administration methods that enhance patient compliance and bioavailability. Innovations such as advanced ...

The major players in the market are Hisamitsu Pharmaceuticals, Bayer AG, Novartis AG, Galderma Holding SA ... VMI provides a holistic overview and global competitive landscape with respect to Region, ...

Read updates from clinical trials and scientific research on Huntington’s disease from Day 1 of the 2024 Huntington Study ...

Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...

UBS analyst Matthew Weston maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF111.00. According to TipRanks, Weston is ranked #1736 out of 9162 analysts ...